Phenotyping-genotyping of alternatively spliced genes in one step : study of CYP3A5*3 polymorphismBUSI, Florent; CRESTEIL, Thierry.Pharmacogenetics and genomics (Print). 2005, Vol 15, Num 6, pp 433-439, issn 1744-6872, 7 p.Article

PharmGKB summary: very important pharmacogene information for CYP3A5LAMBA, Jatinder; HEBERT, Joan M; SCHUETZ, Erin G et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 7, pp 555-558, issn 1744-6872, 4 p.Article

The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variabilityHUAN QIU; MATHÄS, Marianne; NESTLER, Sebastian et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 3, pp 167-178, issn 1744-6872, 12 p.Article

Genetic polymorphism of cytochrome p450 3A5 in chineseCHOU, Fang-Chun; TZENG, Shwu-Jen; HUANG, Jin-Ding et al.Drug metabolism and disposition. 2001, Vol 29, Num 9, pp 1205-1209, issn 0090-9556Article

Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives : enzyme specificity, interindividual distribution and metabolic contribution in human liverMAGANG SHOU; MARTINET, M; KORZEKWA, K. R et al.Pharmacogenetics (London). 1998, Vol 8, Num 5, pp 391-401, issn 0960-314XArticle

CYP3A5 genotype is associated with elevated blood pressureFROMM, Martin F; SCHMIDT, Bernhard M. W; PAHL, Andreas et al.Pharmacogenetics and genomics (Print). 2005, Vol 15, Num 10, pp 737-741, issn 1744-6872, 5 p.Article

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantationGOTO, Maki; MASUDA, Satohiro; KIUCHI, Tetsuya et al.Pharmacogenetics (London). 2004, Vol 14, Num 7, pp 471-478, issn 0960-314X, 8 p.Article

Differential impact of the CYP3A5^*1 and CYP3A5^*3 alleles on pre-dose concentrations of two tacrolimus formulationsWEHLAND, Markus; BAUER, Steffen; BRAKEMEIER, Susanne et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 4, pp 179-184, issn 1744-6872, 6 p.Article

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish populationMIRGHANI, Rajaa A; SAYI, Jane; BERTILSSON, Leif et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 9, pp 637-645, issn 1744-6872, 9 p.Article

Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populationsSCHIRMER, Markus; TOLIAT, Mohammad R; HABERL, Michael et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 1, pp 59-71, issn 1744-6872, 13 p.Article

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipientsROY, Jean Nicholas; BARAMA, Azemi; POIRIER, Charles et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 9, pp 659-665, issn 1744-6872, 7 p.Article

Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipientsUESUGI, Miwa; MASUDA, Satohiro; KATSURA, Toshiya et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 2, pp 119-127, issn 1744-6872, 9 p.Article

Lipid-lowering response to statins is affected by CYP3A5 polymorphismKIVISTÖ, Kari T; NIEMI, Mikko; SCHAEFFELER, Elke et al.Pharmacogenetics (London). 2004, Vol 14, Num 8, pp 523-525, issn 0960-314X, 3 p.Article

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patientsHAUFROID, Vincent; MOURAD, Michel; VAN KERCKHOVE, Valérie et al.Pharmacogenetics (London). 2004, Vol 14, Num 3, pp 147-154, issn 0960-314X, 8 p.Article

Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressersTANG, Hui-Lin; XIE, Hong-Guang; YAO YAO et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 11, pp 713-720, issn 1744-6872, 8 p.Article

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in chinese with different CYP3A5 genotypesSHIH, Pei-Shan; HUANG, Jin-Ding.Drug metabolism and disposition. 2002, Vol 30, Num 12, pp 1491-1496, issn 0090-9556, 6 p.Article

The effect of CYP3A5 6986A>G and ABCB 1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysisTERRAZZINO, Salvatore; QUAGLIA, Marco; STRATTA, Piero et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 8, pp 642-645, issn 1744-6872, 4 p.Article

CYP3A5^*1/^*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazoleCHANDEL, Nirupama; AGGARWAL, Pardeep K; MINZ, Mukut et al.Pharmacogenetics and genomics (Print). 2009, Vol 19, Num 6, pp 458-463, issn 1744-6872, 6 p.Article

Significance of the minor cytochrome P450 3A isoformsDALY, Ann K.Clinical pharmacokinetics. 2006, Vol 45, Num 1, pp 13-31, issn 0312-5963, 19 p.Article

The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patientsKREITZ, Reinhold; ZÜRCHER, Heiko; KAIN, Silke et al.Pharmacogenetics (London). 2004, Vol 14, Num 10, pp 665-671, issn 0960-314X, 7 p.Article

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic statesYU, Kyung-Sang; CHO, Joo-Youn; SHIN, Jae-Gook et al.Clinical pharmacology and therapeutics. 2004, Vol 76, Num 2, pp 104-112, issn 0009-9236, 9 p.Article

A significant drug-metabolizing role for CYP3A5?WILLIAMS, J. Andrew; COOK, Jack; HURST, Susan I et al.Drug metabolism and disposition. 2003, Vol 31, Num 12, pp 1526-1531, issn 0090-9556, 6 p.Article

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3a7WILLIAMS, J. Andrew; RING, Barbara J; CANTRELL, Varon E et al.Drug metabolism and disposition. 2002, Vol 30, Num 8, pp 883-891, issn 0090-9556Article

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes : Comparison of k₁ values and impact of CYP3A5 expressionGIBBS, M. A; THUMMEL, K. E; SHEN, D. D et al.Drug metabolism and disposition. 1999, Vol 27, Num 2, pp 180-187, issn 0090-9556Article

Imidazopyridines as selective CYP3A4 inhibitorsXINYI SONG; XIAOHAI LI; RUIZ, Claudia H et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 4, pp 1611-1614, issn 0960-894X, 4 p.Article